1355488-72-0

Upstream product

• 103877-56-1 2,5-difluoro-4-methyl-benzoyl chloride 
• 1355488-71-9 methyl 2,5-difluoro-4-methylbenzoate 
• 103877-80-1 2,5-difluoro-4-methyl-benzoic acid 

Downstream Products

• 1355488-74-2 methyl 4-{[(5-chloro-6-isobutoxypyridin-3-yl)oxy]methyl}-2,5-difluorobenzoate 
• 1355487-27-2 4-{[(5-chloro-6-isobutoxypyridin-3-yl)oxy]methyl}-2,5-difluoro-N-(methylsulfonyl)benzamide diethylamine salt 
• 1355488-77-5 4-((5-chloro-6-isobutoxypyridin-3-yloxy)methyl)-2,5-difluorobenzoic acid 
• 1355636-86-0 methyl 2,5-difluoro-4-[(3-methoxyphenoxy)methyl]benzoate 
• 1355636-87-1 2,5-difluoro-4-[(3-methoxyphenoxy)methyl]benzoic acid 

Relevant academic research and scientific papers

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar1, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

CHEMICAL COMPOUNDS

PC71695A Abstract Chemical Compounds The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I):10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.